A Study of Continuous Infusions of HNO (Nitroxyl) Donor in Patients With Heart Failure and Impaired Systolic Function

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Heart failure with reduced ejection fraction (LVEF on echocardiogram of 40% or less) * Stable guideline directed therapy for heart failure including oral diuretics, ACEi, ARBs, ARNi, MRAs, and β blockers as tolerated, with no dose changes of these medications in the past 2 weeks * Have screening values of NT pro-BNP ≥ 125 pg/mL (15 pmol/L) or BNP ≥ 35 pg/mL (10 pmol/L) Exclusion Criteria: * Systolic blood pressure (SBP) \< 110 mm Hg at screening or pre-randomization * Heart rate \< 50 beats per minute (bpm) or \> 90 bpm at screening or pre-randomization * Permanent Atrial Fibrillation, Atrial Flutter or having Atrial Fibrillation, Atrial Flutter * Estimated glomerular filtration rate (eGFR) \< 15 ml/min/1.73 m2 * Ventricular assist device or prior heart transplant * Prior solid organ transplant * Body weight \< 45 kg or ≥ 140 kg * Low quality echocardiographic visualization windows and image acquisition * Permanent paced rhythm (VVI, DDD or BiV pacing) Other protocol defined inclusion/exclusion criteria could apply